Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Eltrombopag, Low-Dose Rituximab, and High-Dose Dexamethasone Combination for Patients with Newly Diagnosed Immune Thrombocytopenia: A Pilot "Total Therapy" Study

David Gomez-Almaguer, MD, Olga Cantu-Rodriguez, MD, Cesar Homero Gutierrez-Aguirre, MD, Jose Carlos Jaime-Perez, MD PhD, Luz C. Tarin-Arzaga, MD, Monica Sanchez Cardenas, MD, Rosa Elena Lozano-Morales, MD, Guillermo Sotomayor Duque, MD, Daniela Cárdenas-Araujo, MD, Andres Gomez-de Leon, MD, Paola Santana-Hernandez, Perla Rocío Colunga-Pedraza, MD

Blood (2016) 128 (22): 1369.

https://doi.org/10.1182/blood.V128.22.1369.1369

Published: 2016

Journal Articles

Low-Dose Nilotinib and Imatinib Combination In CML Patients, With Failure, Suboptimal Response Or Treatment Intolerance To First Line Imatinib Treatment. A Pilot Study

David Gomez-Almaguer, MD, Roxana Saldaña-Vázquez, MD, Olga Graciela Cantú-Rodríguez, MD, Cesar H Gutiérrez-Aguirre, MD, Jose Carlos Jaime-Pérez, MD, Luz C. Tarin-Arzaga, MD

Blood (2013) 122 (21): 4034.

https://doi.org/10.1182/blood.V122.21.4034.4034

Published: 2013

Journal Articles

Eltrombopag and High-Dose Dexamethasone As First Line Treatment For ITP

David Gomez-Almaguer, MD, Miguel Angel Herrera-Rojas, MD, Andres Gomez-de Leon, MD, Olga Graciela Cantú-Rodríguez, MD, Cesar H Gutiérrez-Aguirre, MD, Jose Carlos Jaime-Pérez, MD, Luz C. Tarin-Arzaga, MD, Guillermo J. Ruiz-Arguelles, MD, FRCP (Glasg), MACP, Jesus Hernandez-Reyes, MD

Blood (2013) 122 (21): 3544.

https://doi.org/10.1182/blood.V122.21.3544.3544

Published: 2013

Journal Articles

Low-Dose Rituximab and High-Dose Dexamethasone As Front-Line Therapy in Adult Patients with Primary Immune Thrombocytopenia

David Gomez-Almaguer, MD, Luz C. Tarin-Arzaga, MD, Brizio Moreno-Jaime, MD, Jose C. Jaime-Pérez, MD, Adrián A. Ceballos-López, MD, Guillermo J. Ruiz-Argüelles, MD, Guillermo J. Ruiz-Delgado, MD, Olga Cantú-Rodríguez, MD, Cesar H Gutiérrez-Aguirre, MD

Blood (2012) 120 (21): 3332.

https://doi.org/10.1182/blood.V120.21.3332.3332

Published: 2012

Journal Articles

Is There a Benefit of Adding Rituximab to CHOP in the Overall Survival of Patients with B-Cell Non-Hodgkin′s Lymphoma in a Developing Country ?

Guillermo J. Ruiz-Delgado, MD, David Gomez Almaguer, MD, Luz C. Tarin-Arzaga, MD, Olga Cantú-Rodríguez, MD, Carlos Alarcon-Urdaneta, MD, Uxmal Rodriguez-Morales, MD, Jackeline Calderon-García, MD, Omar Fernandez-Vargas, MD, Maryel Montes-Montiel, MD, Monica Sanchez-Cardenas, MD, Guillermo J. Ruiz-Arguelles, MD, FACP, FRCP (Glasg)

Blood (2012) 120 (21): 4892.

https://doi.org/10.1182/blood.V120.21.4892.4892

Published: 2012

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Eltrombopag, Low-Dose Rituximab, and High-Dose Dexamethasone Combination for Patients with Newly Diagnosed Immune Thrombocytopenia: A Pilot "Total Therapy" Study

Low-Dose Nilotinib and Imatinib Combination In CML Patients, With Failure, Suboptimal Response Or Treatment Intolerance To First Line Imatinib Treatment. A Pilot Study

Eltrombopag and High-Dose Dexamethasone As First Line Treatment For ITP

Low-Dose Rituximab and High-Dose Dexamethasone As Front-Line Therapy in Adult Patients with Primary Immune Thrombocytopenia

Is There a Benefit of Adding Rituximab to CHOP in the Overall Survival of Patients with B-Cell Non-Hodgkin′s Lymphoma in a Developing Country ?

Email alerts

ASH Publications

American Society of Hematology

Update search

Eltrombopag, Low-Dose Rituximab, and High-Dose Dexamethasone Combination for Patients with Newly Diagnosed Immune Thrombocytopenia: A Pilot "Total Therapy" Study

Low-Dose Nilotinib and Imatinib Combination In CML Patients, With Failure, Suboptimal Response Or Treatment Intolerance To First Line Imatinib Treatment. A Pilot Study

Eltrombopag and High-Dose Dexamethasone As First Line Treatment For ITP

Low-Dose Rituximab and High-Dose Dexamethasone As Front-Line Therapy in Adult Patients with Primary Immune Thrombocytopenia

Is There a Benefit of Adding Rituximab to CHOP in the Overall Survival of Patients with B-Cell Non-Hodgkin′s Lymphoma in a Developing Country ?

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only